{"id":"docetaxel-ddp","safety":{"commonSideEffects":[{"rate":"60–80","effect":"Neutropenia"},{"rate":"40–60","effect":"Anemia"},{"rate":"20–40","effect":"Thrombocytopenia"},{"rate":"40–60","effect":"Nausea and vomiting"},{"rate":"20–40","effect":"Peripheral neuropathy"},{"rate":"10–20","effect":"Nephrotoxicity"},{"rate":"5–15","effect":"Ototoxicity"},{"rate":"50–80","effect":"Alopecia"}]},"_chembl":{"chemblId":"CHEMBL92","moleculeType":"Small molecule","molecularWeight":"807.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel (a taxane) stabilizes microtubules and prevents their disassembly, disrupting mitotic spindle formation and cell division. Cisplatin (DDP) forms DNA adducts and crosslinks, preventing DNA replication and transcription. The combination exploits complementary mechanisms to enhance cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"Docetaxel/DDP is a combination chemotherapy regimen that uses a taxane microtubule stabilizer paired with a platinum-based DNA crosslinking agent to inhibit cancer cell division and induce apoptosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:38.775Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic non-small cell lung cancer"},{"name":"Gastric cancer"},{"name":"Head and neck cancer"},{"name":"Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT07496190","phase":"PHASE2","title":"Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-01","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":59},{"nctId":"NCT05063552","phase":"PHASE2, PHASE3","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-13","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":430},{"nctId":"NCT06524544","phase":"PHASE3","title":"A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-12-02","conditions":"Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma","enrollment":320},{"nctId":"NCT03493425","phase":"PHASE2","title":"Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-03-12","conditions":"Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","enrollment":82},{"nctId":"NCT01810913","phase":"PHASE2, PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":"Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","enrollment":613},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT04030455","phase":"PHASE2","title":"Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-07","conditions":"Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8","enrollment":28},{"nctId":"NCT00707473","phase":"PHASE2","title":"Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-06-16","conditions":"Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma","enrollment":31},{"nctId":"NCT00588770","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-08","conditions":"Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":403},{"nctId":"NCT05753306","phase":"PHASE2","title":"Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-04-20","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":40},{"nctId":"NCT03582475","phase":"PHASE1","title":"Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-01-11","conditions":"Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma","enrollment":15},{"nctId":"NCT02495896","phase":"PHASE1","title":"Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2015-09-03","conditions":"Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma","enrollment":61},{"nctId":"NCT05541016","phase":"PHASE2","title":"De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-02-21","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":455},{"nctId":"NCT00334815","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-15","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma","enrollment":29},{"nctId":"NCT03158129","phase":"PHASE2","title":"Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06-16","conditions":"Stage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":101},{"nctId":"NCT00324805","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-07-19","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":1501},{"nctId":"NCT01064479","phase":"PHASE2","title":"Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-02-05","conditions":"Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity","enrollment":123},{"nctId":"NCT00254384","phase":"PHASE1","title":"Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-10-05","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":50},{"nctId":"NCT02225405","phase":"PHASE1","title":"Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-04-03","conditions":"Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7","enrollment":26},{"nctId":"NCT06190782","phase":"PHASE3","title":"Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-09-27","conditions":"Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy","enrollment":354},{"nctId":"NCT02607423","phase":"PHASE2","title":"Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery","status":"WITHDRAWN","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2015-11-19","conditions":"Stage IIIA Non-Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT05622474","phase":"NA","title":"A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-11-30","conditions":"Nasopharyngeal Carcinoma","enrollment":236},{"nctId":"NCT04437329","phase":"PHASE3","title":"Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2020-08-01","conditions":"Nasopharyngeal Carcinoma","enrollment":352},{"nctId":"NCT04508816","phase":"PHASE2","title":"Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy","status":"COMPLETED","sponsor":"Fudan University","startDate":"2016-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":45},{"nctId":"NCT04508829","phase":"PHASE2","title":"Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2016-01-01","conditions":"Oropharyngeal Carcinoma","enrollment":52},{"nctId":"NCT05232552","phase":"PHASE2","title":"Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":37},{"nctId":"NCT04009265","phase":"PHASE3","title":"Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2019-08-23","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":819},{"nctId":"NCT02512315","phase":"PHASE3","title":"A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Nasopharyngeal Carcinoma","enrollment":192},{"nctId":"NCT04576143","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-09-20","conditions":"HER2-negative Breast Cancer, Neoadjuvant Chemotherapy","enrollment":260},{"nctId":"NCT00896181","phase":"PHASE2","title":"Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2008-12-10","conditions":"Stage II Lymphoepithelioma of the Nasopharynx, Stage II Squamous Cell Carcinoma of the Nasopharynx, Stage III Lymphoepithelioma of the Nasopharynx","enrollment":26},{"nctId":"NCT03908372","phase":"PHASE2, PHASE3","title":"Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2019-06-15","conditions":"Stage II, III, Nasopharyngeal Squamous Cell Carcinoma, Induction Chemotheray","enrollment":120},{"nctId":"NCT04138992","phase":"PHASE2, PHASE3","title":"A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2020-08-01","conditions":"Disease Free Survival","enrollment":150},{"nctId":"NCT02627807","phase":"NA","title":"Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-12","conditions":"Nasopharyngeal Neoplasms","enrollment":386},{"nctId":"NCT02403531","phase":"PHASE2","title":"Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal Cancer","status":"COMPLETED","sponsor":"Mian XI","startDate":"2015-05-01","conditions":"Neoplasms","enrollment":110},{"nctId":"NCT02508246","phase":"PHASE1","title":"WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-07-22","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":12},{"nctId":"NCT03604965","phase":"PHASE3","title":"GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-07-21","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":204},{"nctId":"NCT01557959","phase":"PHASE2","title":"Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2007-07","conditions":"Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer","enrollment":45},{"nctId":"NCT02035527","phase":"PHASE1","title":"Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2014-04-14","conditions":"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer","enrollment":3},{"nctId":"NCT03117257","phase":"PHASE2","title":"Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2016-08-19","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":144},{"nctId":"NCT00963807","phase":"PHASE2","title":"A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma","enrollment":26},{"nctId":"NCT03006614","phase":"PHASE3","title":"PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer","status":"UNKNOWN","sponsor":"Shi Yanxia","startDate":"2016-04","conditions":"Breast Cancer Model, Effects of Chemotherapy, Breast Cancer","enrollment":320},{"nctId":"NCT03015727","phase":"PHASE3","title":"Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2016-12","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":440},{"nctId":"NCT03002064","phase":"PHASE3","title":"Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-12","conditions":"Esophagus Cancer, Chemotherapy Effects","enrollment":358},{"nctId":"NCT02786641","phase":"PHASE3","title":"Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-08","conditions":"Nasopharyngeal Carcinoma","enrollment":235},{"nctId":"NCT02610556","phase":"PHASE2","title":"Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-01","conditions":"Nasopharyngeal Carcinoma","enrollment":130},{"nctId":"NCT02621970","phase":"PHASE3","title":"Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-01","conditions":"Nasopharyngeal Carcinoma","enrollment":534},{"nctId":"NCT00253370","phase":"PHASE2","title":"Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-10","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer","enrollment":44},{"nctId":"NCT02047487","phase":"","title":"After Induction Chemotherapy of DP Plus DDP Concurrent Radiotherapy With and Without Bevacizumab Study","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2013-05","conditions":"Head and Neck Neoplasms","enrollment":120},{"nctId":"NCT01999933","phase":"PHASE2, PHASE3","title":"Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer","status":"UNKNOWN","sponsor":"Mei Shi","startDate":"2013-11","conditions":"Cervical Cancer, Toxicity Due to Radiotherapy","enrollment":600},{"nctId":"NCT00020709","phase":"PHASE3","title":"Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-06","conditions":"Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer","enrollment":840},{"nctId":"NCT00042835","phase":"PHASE1","title":"Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-05","conditions":"Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer","enrollment":48},{"nctId":"NCT00174629","phase":"PHASE3","title":"GILT Docetaxel - Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-06","conditions":"Lung Neoplasms","enrollment":449}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":49,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Docetaxel/DDP","genericName":"Docetaxel/DDP","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel/DDP is a combination chemotherapy regimen that uses a taxane microtubule stabilizer paired with a platinum-based DNA crosslinking agent to inhibit cancer cell division and induce apoptosis. Used for Advanced or metastatic non-small cell lung cancer, Gastric cancer, Head and neck cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}